logo  Click here is a medical destination site in-progress by the team at
Catheter-Related Bloodstream Infections


CRBSI can be deadly.  A catheter-related bloodstream infection can lead to sepsis and even death.  Even with good aseptic protocols to keep skin and catheter sites clean, you can still get a CRBSI. It's root cause is in the buildup of biofilm which creates an attractive environment for bacteria and infection.  As bacteria gathers around an infected catheter, it naturally begins to disseminate through the bloodstream. CRBSI must be prevented and treated.  Many companies are working on solutions to CRBSI now.



CRBSI is a complex medical problem that challenges the viability of extended use of bloodstream catheters, due to bloodstream infections often caused by the catheters, or at least bacteria that gathers around the catheters either inside the bloodstream, or at the entry site. The medical world has been trying to tackle CRBSI for well over a decade. CRBSI is an acronym for catheter-related bloodstream infections.  In the United States intensive care units (ICUs) alone, there are 15 million "central venous catheter (CVC) days" each year.  During that same time frame, there are an average of 80,000 CRBSI cases in those ICUs, and 250,000 CRBSI cases in the entire hospital.  These infections represent a considerable toll on patients and  hospital resources.  There are additional CRBSI cases outside the hospital environments, for example in ambulatory dialysis patients, who visit outpatient dialysis clinics several times per week.

CRBSI Prevention

The United States Centers for Disease Control (CDC) has developed guidelines to try to help minimize CRBSI occurence, that includes measures such as good aseptic protocols, avoidance of certain kinds of susceptible catheters, placement of catheters, daily site care protocols, and more.  Prevention measures go a long way to slow the occurence of CRBSI, but are not total solutions, as the statistics show.  Innovative prevention measures are in the pipeline, and are only hindered by the juggernaut and politics at the FDA.

CRBSI Treatment

The treatment of CRBSI has been hampered by an alarming and growing resistance to antibiotics that have traditionally been used to fight bloodstream infections.  This is often referred to as MRSA (methicillin resistant staph aureus) and MRSE (methicillin resistant staphyloccus epidermus), along with some other bacteria strains that are vancomycin resistant.  CRBSI falls in the broader category of hospital acquired infections (HAIs) and as such, not only is it difficult medically to resolve, but it also represents significant liability risk in the clinical setting.  The toll on patients, physicians, caregivers and the clinics all make for great urgency to get treatments approved and available to clinicians stat.

We plan to develop this site into a comprehensive CRBSI resource site in the coming months. We thank you for visiting now, and in the future as the site evolves. Feel free to contact us if you have anything to add.


 Site Map
" is available for purchase, prior to development.  Please contact us for more information."

- The Team -